Studies among HIV-seronegative and HIV-infected individuals have reported an association between HBV or HCV infections and the development of cardiovascular diseases (CVD), often assessed using surrogate or subclinical end points of atherosclerosis (that is, presence of carotid artery plaques, intima media thickening or coronary stenosis) and rarely using clinical end points (myocardial infarction [MI] or stroke). However, the limited epidemiological and clinical data available among both patient groups are conflicting ( Table 1) . The potential atherogenic effect of chronic hepatitis virus infections might be caused by chronic inflammation, which could accelerate the underlying atherosclerotic process or lead to instability of existing atherosclerotic plaques. By contrast, decreased plasma lipid levels [1] [2] [3] [4] , and decreased C-reactive protein levels associated with chronic HCV infection [5] , might have a possible protective effect against CVD.
Inflammation is a component in the pathogenesis of atherosclerosis [6] . Since the discovery in 1978 of an avian herpesvirus that induced atherosclerosis in chickens [7] , the role of various infectious agents in the development of CVD has been investigated, including Chlamydia pneumoniae, Helicobacter pylori, Porphyromonas gingivalis, cytomegalovirus, herpes simplex virus and hepatitis A virus [6, [8] [9] [10] [11] . Although seroepidemiological studies have found strong associations, the causative role of these microorganisms remained controversial [12, 13] , and experimental work suggested that inflammation per se, rather than specific infectious agents, might contribute to atherosclerosis [14, 15] . Among HIV-seropositive individuals, MI was previously associated with exposure to antiretroviral therapy (ART) -particularly certain classes and drugs within classes -in addition to traditional CVD risk factors [16] [17] [18] [19] [20] [21] . Subsequently, endothelial dysfunction, which is an early marker of atherosclerosis, and plasma Table 1 . Literature review on the association between hepatitis B or C infections and cardiovascular diseases a Age-adjusted (not adjusted for other variables because of low number of end points). CI, confidence interval; CVD, cardiovascular disease; ICD-9, International Statistical Classification of Diseases and Related Health Problems-9; MI, myocardial infarction; NS, non-significant; OR, odds ratio. biomarkers of atherogenic cytokines or thrombogenic products of the coagulation cascade, were found to be associated with certain antiretroviral drugs [19, 22, 23] . However, such markers were also present in HIVinfected individuals without ART, and in HIV-infected 'elite' controllers with low or undetectable viraemia and preserved immune function, but not in HIV-negative control individuals, suggesting that HIV infection per se can cause premature atherosclerosis [24] . In HIV-HCVcoinfected individuals on ART, some plasma markers of atherosclerosis appeared to be higher than among HIVmonoinfected individuals on ART [25] .
We investigated the association between HBV or HCV infection and MI in a large prospective observational cohort of HIV-infected individuals. As an additional analysis, we studied whether these hepatitis virus infections were associated with the development of stroke.
Methods

Design
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has previously been described in detail [16] [17] [18] [19] 26] . In brief, it is a collaborative, observational study of 11 cohorts that includes 33,347 HIV type-1-infected individuals prospectively followed at 212 clinics in Europe, the United States and Australia. The study began in December 1999 and the latest follow-up for this analysis was on 1 February 2007. Although the primary end point of the study is MI, other clinical end points, including stroke as well as all deaths, are prospectively collected [17] .
Data collection
All participants were under prospective follow-up in their individual cohorts at the time of enrolment in the D:A:D study. Standardized data collection forms containing demographic, clinical, laboratory and comprehensive information on antiretroviral and selected other medications were completed at each site at least every 8 months. Results of HBV and HCV serologies and hepatitis virus load assessments, if available, had been collected since 2004 (including previously collected data by the participating cohorts). All incident cases of MI were reported to the study coordinating office for validation and coding. Reported MIs were classified as definite, possible or unclassifiable, according to criteria applied in the WHO MONICA study [27] . Ascertainment and adjudication of MI in the D:A:D cohort have previously been published in detail [16, 17, 19] .
For reported strokes, detailed information was collected, including symptoms, duration of symptoms, central nervous system imaging findings by computerized tomography or magnetic resonance scanning, spinal fluid examination where available, and information of underlying disease possibly related to the episode (for example, hypertension, atrial fibrillation, cocaine use and concomitant central nervous system disease). Reported strokes were classified as definite, stroke-like event or not stroke, and were further classified by the type of lesion as infarction, haemorrhage or unknown. Cerebrovascular lesions that were secondary to other concomitant central nervous system disease, or which did not fulfil the criteria for the stroke definition, were excluded.
Statistical analyses and definitions
Using all prospective data from the D:A:D cohort, we considered whether HBV or HCV coinfections with HIV were associated with incident MI. There were no exclusion criteria for this analysis. Follow-up was considered from the time of entry in D:A:D until the earliest of the following: incident MI, 1 February 2007, death or 6 months after the patient's last clinic visit. Patient follow-up was divided into a series of 1-month periods. Each individual's HBV and HCV status was determined at the start of each period, and their covariate data was also updated at the start of each month. Thus, all covariates that could change over time (including HBV or HCV status) were treated as time-updated covariates in our analyses.
Individuals were classified as HCV-seronegative, HCV-seropositive or unknown (HCV RNA testing has not been routinely performed in all cohorts) and as HBV-seronegative/vaccinated, or as having active (hepatitis B surface antigen-, hepatitis B e antigen-or HBV-DNA-positive) or inactive (positivity for hepatitis B core immunoglobulin G antigen antibody and negativity for hepatitis B surface antigen, positivity for hepatitis B e antigen antibody or HBV-DNA-negative) HBV infection, or unknown infection status [26] . Of note, as hepatitis serology testing has been introduced into routine care for HIV-infected individuals, it was possible for an individual's coinfection status to change from unknown to known over the course of this study.
Poisson regression analysis was used to assess the effect of HCV or HBV infection on the development of MI after adjustment for potential confounders: age, sex, HIV transmission group (homosexual, heterosexual, injection drug use or other/unknown), ethnicity (White, Black, other or unknown), previous clinical AIDS, smoking (current, ex-smoker, never or unknown), family history of CVD, previous MI, clinical cohort, calendar year of diagnosis, body mass index, development of diabetes mellitus (fasting plasma glucose ≥7.0 mmol/l on two consecutive occasions or physician-reported diagnosis with initiation of antidiabetic therapy) and cumulative exposure to the protease inhibitor, non-nucleoside/nucleotide reverse transcriptase inhibitor and nucleoside/nucleotide reverse transcriptase inhibitor drug classes. Subsequent analyses then adjusted for factors that might be affected by HBV or HCV status and thus lie on the causal pathway between hepatitis status and the development of MI, including the most recent measurements of CD4 + T-cell count, nadir CD4 + T-cell count, HIV RNA, total and high-density lipoprotein cholesterol, triglycerides, the development of hypertension and physician-defined lipodystrophy. Of note, there was no requirement for lipids to be measured in a fasting state.
Our main analyses included indicator variables for missing data of hepatitis status. However, this approach to the analysis is known to be suboptimal from a statistical standpoint, and bias could remain; thus, to address this concern, we repeated our analyses using multiple imputation methods to complete the missing data on hepatitis status [28] . We also repeated the analyses using inverse probability weighting methods [29] to account for any differences in censoring mechanism (regarding measured covariates) between those with and without hepatitis coinfection. As an additional analysis, we also considered whether HBV or HCV status was associated with the development of stroke, which is also collected as an end point in the D:A:D study.
Results
Patient characteristics and outcome
We followed 33 
Association between hepatitis B status and myocardial infarction
At enrolment in D:A:D, 18,213 (54.6%) patients were HBV-seronegative or vaccinated, 2,172 (6.5%) were seropositive without markers of active infection and 1,584 (4.8%) had active infection (that is, they were positive for hepatitis B surface antigen, hepatitis B e antigen or HBV DNA). Serostatus was unknown in 11,378 (34.1%) of the patients at enrolment; however, this improved over time as routine testing was introduced, and, overall, only 13.5% of total follow-up included individuals with unknown HBV status. In total, 71.0% of follow-up included individuals who were HBV-seronegative or vaccinated, 9.4% included those with inactive infection and 6.0% included those with active infection.
The rates of MI for those who were HBV-seronegative (or vaccinated) or had inactive or active infection, when allowing each individual's status to change over time, were 3.2 (95% CI 2.8-3.5), 4.2 (95% CI 3.1-5.2) and 2.8 (95% CI 1.8-3.9) per 1,000 person-years, respectively (Table 3 
Association between hepatitis C status and myocardial infarction
At enrolment in D:A:D, 16,731 (50.2%) patients were HCV-seronegative and 5,084 (15.2%) were seropositive. Of those who were seropositive at enrolment, 62 (1.2%) were documented HCV-RNA-negative, 227 (4.5%) were documented HCV-RNA-positive, and the remaining 4,795 (94.3%) had unknown HCV RNA status. Although HCV serostatus was unknown in 11,532 (34.6%) of the patients at study enrolment, this proportion decreased during follow-up as routine testing was introduced and, overall, only 17.6% of follow-up included individuals with unknown HCV serostatus. In total, 61.3% of follow-up included individuals who were seronegative and 21.1% included those who were seropositive.
When taking into account changes in HCV status over time, the rates of MI for those who were HCVseronegative and HCV-seropositive were 3.3 (95% CI 3.0-3.7) and 2.7 (95% CI 2.2-3.3) per 1,000 personyears, respectively (Table 3) . After adjustment for patient characteristics, there was no relationship between HCV seropositivity (relative rate 0.86 [95% CI 0.62-1.19]) and the development of MI (Table 4) ; as before, further adjustment for covariates that might lie on the causal pathway between HCV infection and the development of MI did not reveal any additional associations.
Of note, only five MIs occurred in patients with active HBV infection who were HCV-seropositive. There was no evidence that coinfection with both viruses had an effect on the risk of MI, although analyses were limited because of the small number of coinfected patients. [20, 21] . Furthermore, type-2 diabetes mellitus in HIV-infected individuals might be associated with HCV coinfection [30] ; adjustment for this might, therefore, partly control for differences in lifestyle factors. As previously reported, traditional CVD risk factors, similar to those identified in the non-HIVinfected population, and, in addition, ART with protease inhibitors, abacavir and possibly didanosine, have been reported to be associated with MI [16, 17, 19] . Results on the association of HCV monoinfection and subclinical or clinical CVD are conflicting (Table 1) : several cross-sectional and case control studies suggested an increased risk for carotid artery plaques or carotid intima media thickening documented by ultrasonography [31] [32] [33] or coronary stenosis of >50% documented by angiography in HCV-infected individuals, compared with uninfected individuals [34] , whereas other authors found no such association [35] . The design of the studies, the selection of study participants and the lack of comprehensive data on other CVD risk factors in some studies might explain such discrepancies. In terms of association of HCV monoinfection with risk of clinical disease, negative results were reported from a cohort study using the distinct clinical end point of MI [36] . Another clinical end point study, which did not distinguish between HCV and HBV infection, found no association between hepatitis virus infections and MI or stroke [37] . By contrast, a casecontrol study using data of an electronically retrieved cohort of HCV-infected military veterans reported a higher risk of coronary artery disease in HCV-infected patients compared with HCV-seronegative individuals [38] . The sample size of the study was large (Table 1) but the study had major limitations, including the use of International Statistical Classification of Diseases and Related Health Problems-9 codes for the diagnosis of coronary artery disease, lack of adjudication of end points and missing information on important cardiovascular risk factors, such as smoking, body mass index and family history of MI.
Association between HBV or HCV status and stroke
Among HIV-infected individuals, a cross-sectional study found no increased risk associated with HCV coinfection for carotid artery plaques or carotid intima media thickening documented by ultrasonography [35] . By contrast, a cross-sectional study of 395 HIV-infected individuals comparing HCV-coinfected and HCV-seronegative patients with respect to self-reported retrospective information on ever having had peripheral vascular disease, a stroke or a heart attack, 13 versus 1 heart attacks were reported in the two groups, respectively, which resulted in a significant age-adjusted association between MI and HCV infection [39] . However, adjustment for other risk factors was not performed because of the low number of end points. Little association between HCV and MI (odds ratio 1. (Table 1) , whereas the 'negative' studies were published in 2005 or thereafter. This might rather be a result of publication bias (positive studies that are more interesting are published first and the negative studies are published to dispute them) than the selection of different populations. Of note, only three reports on HIV-HCV-coinfected individuals have been published so far, and all of them assessed patients in the era of combination ART [35, 39, 40] .
In terms of the association between HBV and CVD, an association of HBV infection and detection of carotid artery plaques was suggested in one cross-sectional study among HIV-uninfected individuals [41] , but no such association was found by other investigators [42] [43] [44] [45] . In a large cohort of 520,000 patients, HBV infection was even found to be associated with a lower risk of developing MI or ischaemic stroke, whereas the risk for haemorrhagic stroke was increased in HBVinfected individuals [45] . To the best of our knowledge, the association between HBV and HIV coinfection and CVD has not been previously studied. This report, which demonstrated no association between HBV and MI, is the first study in a large and well-documented cohort with a suitable statistical approach. In our additional analysis, we found an association between inactive HBV status and the development of stroke, but not between active HBV and stroke. Although we do not have an explanation for this finding, the global P-value for inclusion of HBV status in this model was P=0.13, suggesting that this might simply reflect a chance finding.
The underlying pathogenic mechanism of a potential association between infection and atherosclerosis has not been definitively identified. However, it has been hypothesized that this might involve direct effects of microorganisms on the vascular wall, or indirect effects of infection mediated in the circulation through cytokines, antibodies, acute-phase reactants or products of the coagulation cascade [12, 13] . Consequences of HBV or HCV infections have been noted to be of potential atherogenic effect as well as of possible protective effect against CVD. In HCV-infected individuals, vascular injury could be caused by mixed cryoglobulinaemia [46] or cryofibrinogenaemia [47] , increased soluble intercellular adhesion molecule 1 [48] or the presence of anti-endothelial-cell autoantibodies [49] . Furthermore, both in chronic HCV and HBV infections, increased levels of markers of oxidative stress [50] [51] [52] , the occurrence of vasculitis [53, 54] or the presence of virus in the vascular tissues have been described [55, 56] . By contrast, important CVD risk factors are reduced in HBV-or HCV-infected persons, including serum total cholesterol and triglycerides [3, 4] , as well as levels of clotting factors II and VII, and fibrinogen, which were found to be decreased, particularly among individuals with impaired liver function caused by chronic hepatitis [57] . Clinically, liver cirrhosis is associated with a decreased risk of atherosclerosis and cardiovascular events [58] .
The strengths of the present analyses include the large size and the long-term prospective observation of the cohort, and the number of well-defined end points collected using a structured event reporting form, which was centrally adjudicated. Several limitations should also be noted. Firstly, HBV and HCV serostatus was not available in a subset of patients, and HVC RNA was not available in all HCV-seropositive patients. Of note, as routine hepatitis testing of those infected with HIV has become more common, this information has become available for analysis among a greater proportion of patients in our cohort. When we analysed the association between HBV and HCV status and MI using multiple imputation methods, results were virtually unchanged (relative rates [95% CI] for the HCV-positive, active HBV and inactive HBV groups from these analyses were 0.87 [0.62-1.23], 0.78 [0.53-1.14] and 1.05 [0.79-1.41], respectively). Data on current illicit drug use were not available from most of the cohort studies contributing data to the D:A:D cohort, but we adjusted the multivariate models for HIV transmission group (including injection drug users). Treatment of HCV infection might reduce the effect of coinfection on MI risk, but the use of such treatment was relatively rare until recently. Finally, individuals who are coinfected with HCV tend to come from population groups (for example, injection drug users) who are at increased risk of an early death or loss to follow-up. As a simple means of assessing whether our results were affected by this competing risk of early censoring, we repeated the analyses after excluding patients who died or were lost to follow-up prior to experiencing an MI; the estimates did not change greatly. We also repeated the analyses on the association between HBV and HCV status and MI using inverse probability weights for censoring, again with similar results (relative rates [95% CIs] for the HCV-positive, active HBV and inactive HBV groups from these analyses were 0. Although HBV and HCV coinfection did not contribute to CVD morbidity in our cohort, these viral infections are major causes of other morbidity and mortality among HIV-infected individuals [26] . Thus, primary prevention of hepatitis virus coinfections and their appropriate management are important interventions in the care of HIV-infected individuals. By contrast, there is no indication that HBV or HCV affects the risk of MI and, thus, strategies for prevention or management of this condition in HIV-infected individuals need not be modified in the context of hepatitis virus coinfections. 
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